Inspection Record

Blount Discount Pharmacy, Inc. — FDA 483 Findings

US FDAInspected 2020-02-13Published 2020-03-09 3 findingsMaterial and supplier controlEquipment and facility

View the regulator's official source The source document is always the basis for judgement.

Findings

1Material and supplier control

Non-pharmaceutical grade components are used in the formulation of non-sterile drug products.

2Equipment and facility

Hazardous and highly potent drugs are produced without providing adequate cleaning of work surfaces, utensils, equipment and/or personnel to prevent cross-contamination.

3Equipment and facility

Agents used for cleaning the laminar flow hood and other equipment between products do not include a deactivating agent (e.g.

About this record

Extracted automatically from the document US FDA published on 2020-03-09. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Blount Discount Pharmacy, Inc. company profile — full history US FDA documents, 2020 Go to Findings search